WeTrials
Recruiting

A Phase 1 Study of 5-Fluorouracil in Combination With Abemaciclib in Metastatic, Refractory CRC

What is this study?

This study is testing a new combination of two cancer drugs to see if they can effectively slow down or stop the growth of advanced colorectal cancer. It is specifically for patients whose cancer has not responded well to standard treatments and is looking for a new way to fight these tumors.

Who can participate?

This trial is for adults (18+) with metastatic colorectal cancer that has a specific genetic pattern called 'microsatellite stable.' You must have tried standard treatments before and be physically capable of performing your daily activities.

What will happen?

Participants will receive a combination of the drug Abemaciclib and chemotherapy (5-fluorouracil). You will also have regular check-ups that include blood tests, tissue samples, and imaging scans like CTs or MRIs to monitor how your body is responding.

Where and when?

This study is currently recruiting patients at medical centers in Irvine and Orange, California, as well as the Bronx, New York.

Key Points
  • 1The goal is to find a safe and effective dose of these drugs when taken together.
  • 2The study focuses on patients who have already tried other common treatments without success.
  • 3Participation includes regular health monitoring through scans and lab work.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Microsatellite Stable Colorectal CarcinomaRefractory Microsatellite Stable Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.